Quick Answer
Rapport Therapeutics, Inc. reported Net Income of -$111.48 million for fiscal year 2025.
Rapport Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$111.48M -42.4% |
-$78.31M -125.1% |
-$34.79M | — |
| Diluted EPS | -$2.86 +24.3% |
-$3.78 +83.6% |
-$23.10 | — |
| Total Assets | $512.43M +62.7% |
$314.93M +102.6% |
$155.42M | — |
| Cash and Equivalents | $52.65M -7.3% |
$56.80M -19.0% |
$70.17M | — |
| Stockholders Equity | $484.65M +58.7% |
$305.43M +1291.5% |
-$25.63M -154.8% |
-$10.06M |
| R&D Expense | $94.79M +55.6% |
$60.94M +117.6% |
$28.00M | — |
| Operating Income | -$125.10M -50.6% |
-$83.06M -129.6% |
-$36.18M | — |
| Shares Outstanding | 47.77M +30.6% |
36.58M +777.1% |
4.17M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$26.93M | -53.5% | -0.7% |
| Diluted EPS | September 30, 2025 | -$0.71 | -42.0% | +5.3% |
| Total Assets | September 30, 2025 | $535.32M | +61.7% | +87.5% |
| Cash and Equivalents | September 30, 2025 | $251.36M | +539.4% | +356.5% |
| Stockholders Equity | September 30, 2025 | $511.62M | +58.3% | +94.2% |
| R&D Expense | September 30, 2025 | $22.28M | +43.3% | -1.8% |
| Operating Income | September 30, 2025 | -$29.99M | -38.6% | -1.7% |
| Shares Outstanding | September 30, 2025 | 47.65M | +30.3% | +30.6% |
- Rapport Therapeutics, Inc. reported Net Income of -$111.48 million for fiscal year 2025.
- Rapport Therapeutics, Inc. showed a decrease of -42.4% in Net Income compared to the prior fiscal year.
- Rapport Therapeutics, Inc. reported Diluted EPS of $2.86 per share (loss) for fiscal year 2025.
- Rapport Therapeutics, Inc. showed an increase of +24.3% in Diluted EPS compared to the prior fiscal year.
- Rapport Therapeutics, Inc. reported Total Assets of $512.43 million for fiscal year 2025.
- Rapport Therapeutics, Inc. showed an increase of +62.7% in Total Assets compared to the prior fiscal year.
- Rapport Therapeutics, Inc. reported Cash and Equivalents of $52.65 million for fiscal year 2025.
- Rapport Therapeutics, Inc. showed a decrease of -7.3% in Cash and Equivalents compared to the prior fiscal year.
- Rapport Therapeutics, Inc. reported Stockholders Equity of $484.65 million for fiscal year 2025.
- Rapport Therapeutics, Inc. showed an increase of +58.7% in Stockholders Equity compared to the prior fiscal year.
- Rapport Therapeutics, Inc. reported R&D Expense of $94.79 million for fiscal year 2025.
- Rapport Therapeutics, Inc. showed an increase of +55.6% in R&D Expense compared to the prior fiscal year.
- Rapport Therapeutics, Inc. reported Operating Income of -$125.10 million for fiscal year 2025.
- Rapport Therapeutics, Inc. showed a decrease of -50.6% in Operating Income compared to the prior fiscal year.
- Rapport Therapeutics, Inc. reported Shares Outstanding of 47.77 million shares for fiscal year 2025.
- Rapport Therapeutics, Inc. showed an increase of +30.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: